Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

LY-266,097

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
LY-266,097
Legal status
Legal status
  • In general: uncontrolled
Identifiers
  • 1-[(2-chloro-3,4-dimethoxyphenyl)methyl]-6-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
CAS Number
PubChemCID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC21H23ClN2O2
Molar mass370.88 g·mol−1
3D model (JSmol)
  • CC1=CC2=C(C=C1)NC3=C2CCNC3CC4=C(C(=C(C=C4)OC)OC)Cl
  • InChI=1S/C21H23ClN2O2/c1-12-4-6-16-15(10-12)14-8-9-23-17(20(14)24-16)11-13-5-7-18(25-2)21(26-3)19(13)22/h4-7,10,17,23-24H,8-9,11H2,1-3H3
  • Key:NJLHHCITDFZZSE-UHFFFAOYSA-N

LY-266,097 is a research ligand which acts as apotent andselectiveantagonist for the5-HT2Breceptor, with more than 100x selectivity over the related5-HT2A and5-HT2C receptor subtypes.[1] However, other sources have stated that LY-266,097 is actually abiased agonist of the receptor, selective forGqsignaling but notβ-arrestin2.[2] The drug has been used to study the role of the 5-HT2B receptor in modulatingdopamine release in the brain,[3][4] as well as its involvement in other processes such asallodynia.[5]

References

[edit]
  1. ^Krempaska K, Barnowski S, Gavini J, Hobi N, Ebener S, Simillion C, et al. (January 2020)."Azithromycin has enhanced effects on lung fibroblasts from idiopathic pulmonary fibrosis (IPF) patients compared to controls [corrected]".Respiratory Research.21 (1): 25.doi:10.1186/s12931-020-1275-8.PMC 6964061.PMID 31941499.
  2. ^McCorvy JD, Wacker D, Wang S, Agegnehu B, Liu J, Lansu K, Tribo AR, Olsen RH, Che T, Jin J, Roth BL (August 2018)."Structural determinants of 5-HT2B receptor activation and biased agonism".Nature Structural & Molecular Biology.25 (9):787–796.doi:10.1038/s41594-018-0116-7.PMC 6237183.PMID 30127358.
  3. ^Auclair AL, Cathala A, Sarrazin F, Depoortère R, Piazza PV, Newman-Tancredi A, Spampinato U (September 2010). "The central serotonin 2B receptor: a new pharmacological target to modulate the mesoaccumbens dopaminergic pathway activity".Journal of Neurochemistry.114 (5):1323–1332.doi:10.1111/j.1471-4159.2010.06848.x.PMID 20534001.S2CID 45607832.
  4. ^Devroye C, Cathala A, Haddjeri N, Rovera R, Vallée M, Drago F, et al. (October 2016). "Differential control of dopamine ascending pathways by serotonin2B receptor antagonists: New opportunities for the treatment of schizophrenia".Neuropharmacology.109:59–68.doi:10.1016/j.neuropharm.2016.05.024.PMID 27260325.S2CID 46847094.
  5. ^Pineda-Farias JB, Velázquez-Lagunas I, Barragán-Iglesias P, Cervantes-Durán C, Granados-Soto V (February 2015). "5-HT2B Receptor Antagonists Reduce Nerve Injury-Induced Tactile Allodynia and Expression of 5-HT2B Receptors".Drug Development Research.76 (1):31–39.doi:10.1002/ddr.21238.PMID 25620128.S2CID 26049138.
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Tryptamines
N-Acetyltryptamines
α-Alkyltryptamines
Triptans
Cyclized tryptamines
Isotryptamines
Related compounds
Stub icon

Thispharmacology-related article is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=LY-266,097&oldid=1259435625"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp